Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities

Yonsei University

Status: Completed

Conditions: Pancreatic Cancer

Treatments: Procedure: Blood collection

Study type: Interventional

Funder types: Other

Identifiers

NCT02887599

4-2016-0015

Details and patient eligibility

About

Pancreatic cancer is the 5th leading cause of cancer death and the worst prognostic cancer in the world. This is due to high recurrent rate after surgical resection and poor response to chemotherapy and radiotherapy.

Recent studies revealed that peri-tumoral structure and patients' immune status including cytotoxic immunity played significant role in the bad behavior of pancreatic cancer. While past studies focused on oncogenes and tumor suppressor genes, recent studies focused on patients' own immunity. Patients' immunity modified by cancer cells is found to be correlated to cancer progression and metastasis.

Natural killer cells, playing an important role in cytotoxic immune system, are revealed to be decreased in patients with lung cancer, ovarian cancer, prostate cancer, colorectal cancer, and breast cancer. And in melanoma mouse model, when NK cell was suppressed, cancer progression and metastasis were accelerated.

This study sought to find the correlation of patients' cytotoxic immune status to cancer progression and status by measurement of NK cell activity in pancreatic cancer patients. This would be basic support to construct a prognostic model of pancreatic cancer for early metastasis and post operational recurrence.

Enrollment: 203 patients

Sex: All

Ages: 19 to 84 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age over 18 and under 85
• Control group : incidental found benign pancreatic cyst, non-neoplastic gall bladder polyp (ex, cholesterol polyp), healthy people having no evidence of malignancy in check up within 1 year
• Patient group : histological diagnosed pancreatic cancer patients, clinically diagnosed pancreatic cancer patients by radiologic evaluation
• Agreed to enroll the study and signed informed consent

Exclusion criteria

• Patients with other malignancies within 5 years
• Patients treated with steroid due to any reason within 1 year
• Not signed informed consent

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

203 participants in 2 patient groups

Patient Group

Other group

Description:

Pancreatic cancer patients

Treatment:

Procedure: Blood collection

Control Group

Other group

Description:

Healthy people without evidence of malignancy

Treatment:

Procedure: Blood collection